28.5 C
New York
Thursday, June 18, 2026

Tag: screening

newssourceFORcompanyinformationcontent1marketreleases

10 ARTS Foundation and NYFA Launch Groundbreaking Creative Arts Program for NYC Veterans

Announcing the launch of the PFC Joseph P. Dwyer Veterans Creative Arts Program 
Announcing the launch of the PFC Joseph P. Dwyer Veterans Creative Arts Program

Iconic Beginnings: Legacies in Motion

103 Years of Bringing Native Art to the World SANTA FE, N.M., June 25, 2025 /PRNewswire/ -- The Southwestern Association for Indian Arts (SWAIA) is...

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

Health and Wellness Market Size Worth USD 11 Trillion by 2034

The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives. 
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.

Generative AI Services Market to Hit USD 43.8 Billion by 2030, Fueled by SaaS & Healthcare Demand | Valuates Reports

Generative AI Services Market is Segmented by Type (IaaS, PaaS, SaaS), by Application (Marketing and Advertising, Technology, Consulting, Teaching, Accounting, Healthcare). BANGALORE, India, June 24,...

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to...

For media and investors only

PRIORITIZE PROSTATE SCREENING–IT’S THE BEST DEFENSE AGAINST PROSTATE CANCER, SAYS PROCURE

SOMERSET, N.J., June 23, 2025 /PRNewswire/ -- ProCure Proton Therapy Center reminds area residents about the critical importance to men of prostate-specific antigen (PSA)...

SciBase resolves on a directed share issue of approximately SEK 11 million

STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the...

New Security Screening Line at Halifax Stanfield International Airport (YHZ) includes CATSA CT Technology

OTTAWA, ON, June 23, 2025 /CNW/ - Halifax Stanfield International Airport (YHZ) becomes the first airport in Atlantic Canada to introduce the Canadian Air...

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

 – Broad label inclusive of all ages and disease severities –  – Launch to be initiated in Germany – WARREN, N.J., June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc....

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsScreening

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers